Angelos Angelakas
A5077735441- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Healthcare cost, quality, practices
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Body Contouring and Surgery
- Peptidase Inhibition and Analysis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Surgical Treatments
- Pulmonary Hypertension Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Cancer survivorship and care
- Drug Transport and Resistance Mechanisms
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Cancer Research and Treatments
- Cancer-related gene regulation
The Christie NHS Foundation Trust
2021-2025
The Christie Hospital
2022
University Hospitals of Morecambe Bay NHS Foundation Trust
2020-2021
Royal Lancaster Infirmary
2020
Abstract Background Cancers affecting < 6/100,000/year are classified as rare, but they account for up to 25% of all cancers and associated with worse 5-year survival than common cancers. Early-phase clinical trials (EPCTs) may represent a viable treatment option patients rare have evolved significantly novel designs the increasing use precision medicine. Methods A retrospective study referred large EPCT team at UK specialist centre over 5 years (2016–2020) was conducted. Patient...
Cancer patients are at increased risk of death from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). and its treatment affect many haematological biochemical parameters, therefore we analysed these prior to during disease 2019 (COVID-19) correlated them with outcome.
Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, monitoring early intervention critical. We sought to identify features disease in patients predicting build a decision support online tool, Risk Oncology Evaluation Tool (CORONET).
Early onset Colorectal Cancer (EOCRC), defined as those diagnosed under the age of 50, has been increasing rapidly since 1970. UK data on EOCRC are currently limited and better understanding condition is needed.
Abstract Effective treatment for gastrointestinal (GI) cancers is a significant unmet need. Gremlin-1, secreted by cancer-associated fibroblasts, downregulates bone morphogenetic proteins (BMP), members of the transforming growth factor β superfamily, resulting in tumor stemness, hyperproliferation, and invasiveness. Ginisortamab, fully human IgG4P mAb, neutralizes gremlin-1, thus restoring BMP signaling. Preclinical studies showed that ginisortamab binds to gremlin-1 has antitumor activity...
Chronic obstructive pulmonary disease (COPD) is highly prevalent worldwide. Its morbidity and mortality are increasing it predicted to be the third leading cause of death by 2020. COPD cardiovascular (CVD) chronic conditions that share many risk factors a complex pathophysiology. Current literature has closely focused on relationship between these two diseases today considered an independent factor for CVD, which in approximately 50% patients. Coronary artery disease, congestive heart...
Abstract Background Cancer patients are at increased risk of severe COVID-19. As COVID-19 presentation and outcomes heterogeneous in cancer patients, decision-making tools for hospital admission, severity prediction monitoring early intervention critical. Objective To identify features predicting disease build a decision-support online tool; Risk Oncology Evaluation Tool (CORONET) Method Data was obtained consecutive with active laboratory confirmed presenting 12 hospitals throughout the...
Patients with cancer have been shown to increased risk of COVID-19 severity. We previously built and validated the Risk in Oncology Evaluation Tool (CORONET) predict likely severity patients active who present hospital. assessed differences presentation outcomes COVID-19, depending on wave pandemic. examined features at worldwide, waves pandemic: 1 D614G (n = 1430), 2 Alpha 475), 4 Omicron variant 63, UK Spain only). The performance CORONET was evaluated 258, 48, 54 for each wave,...
Background: Patients with cancer are at increased risk of severe COVID-19, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction monitoring early intervention critical. We sought to identify features COVID-19 in patients predicting disease build a decision-support online tool; Risk Oncology Evaluation Tool (CORONET).Methods: active (stage I-IV) laboratory confirmed presenting hospitals worldwide were included. Discharge (within...
2522 Background: Pre-existing autoimmune disease (AID) potentially increases the propensity for development of immune related adverse events (irAE) in response to oncological checkpoint inhibitors (ICIs) is biologically plausible and clinically observed. However, due consistent clinical trial exclusion those with pre-existing AID, impact on frequency severity irAEs uncertain. Here we analyse this relationship a large, real-world, UK multi-centre cohort. Methods: A retrospective analysis 2049...